|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2005-5-4
|
|
pubmed:abstractText |
Thymic carcinoma is a rare mediastinal neoplasm with a poor prognosis due to delayed diagnosis and highly malignant behavior. To evaluate 7 serum tumor markers and the outcome of treatment, 11 stage III-IVb thymic carcinomas undergoing multimodality treatment were reviewed. High levels of serum CYFRA21-1 were detected in 5 patients (45%) and correlated with the progression of disease. Of the patients, 6 underwent surgery. The median survival time was 38.4 months, and the 5-year survival rate was 15.6%. The metastatic stage (IVb) and treatment without resection were significantly associated with poorer overall survival (p=0.0034 and p=0.0041, respectively). Our data demonstrated that serum CYFRA21-1 may represent a potential new biomarker in thymic carcinoma. Stage may provide a basis for prognosis in stage III-IVb thymic carcinoma, and resection is one of the most important parts of multimodality treatment for advanced thymic carcinoma. Effective neoadjuvant treatment is therefore essential.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1021-335X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1127-31
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:15870932-Aged,
pubmed-meshheading:15870932-Antigens, Neoplasm,
pubmed-meshheading:15870932-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15870932-Combined Modality Therapy,
pubmed-meshheading:15870932-Disease Progression,
pubmed-meshheading:15870932-Female,
pubmed-meshheading:15870932-Humans,
pubmed-meshheading:15870932-Keratin-19,
pubmed-meshheading:15870932-Keratins,
pubmed-meshheading:15870932-Male,
pubmed-meshheading:15870932-Mediastinal Neoplasms,
pubmed-meshheading:15870932-Middle Aged,
pubmed-meshheading:15870932-Neoplasm Staging,
pubmed-meshheading:15870932-Prognosis,
pubmed-meshheading:15870932-Radiotherapy Dosage,
pubmed-meshheading:15870932-Survival Rate,
pubmed-meshheading:15870932-Thymoma,
pubmed-meshheading:15870932-Thymus Neoplasms,
pubmed-meshheading:15870932-Treatment Outcome,
pubmed-meshheading:15870932-Tumor Markers, Biological
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Multimodality therapy and significance of serum CYFRA21-1 for thymic carcinoma.
|
|
pubmed:affiliation |
Division of Thoracic Diseases, Chiba Cancer Center, 666-2 Nitona-cho, Chuoh-ku, Chiba 260-8717, Japan. smakoto@chiba-cc.jp
|
|
pubmed:publicationType |
Journal Article
|
